Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

Zacks06-20

Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, is having a good run year to date (YTD). Shares of the company have risen 13.6% YTD against the industry’s decline of 7%. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444402996?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","is_english":true,"pubTime":"2024-06-20 01:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2444402996","market":"us","top_or_hot":-1,"title":"Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?","media":"Zacks","content":"<div>\n<p>Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, is having a good run year to date (YTD).\nShares of the company have risen 13.6% YTD against the industry’s decline of 7%.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/terns-tern-gains-13-6-172700222.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns (TERN) Gains 13.6% YTD: Will the Momentum Continue?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-20 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/terns-tern-gains-13-6-172700222.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, is having a good run year to date (YTD).\nShares of the company have risen 13.6% YTD against the industry’s decline of 7%.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/terns-tern-gains-13-6-172700222.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/terns-tern-gains-13-6-172700222.html","article_id":"2444402996","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444402996","pubTimestamp":1718818020,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, is having a good run year to date .Shares of the company have risen 13.6% YTD against the industry’s decline of 7%.The outperformance can be attributed to encouraging pipeline progress.Terns is developing a portfolio of small molecule product candidates in the oncology and obesity space. The pipeline contains three clinical-stage development programs, including an allosteric BCR-ABL inhibitor, a small molecule glucagon-like peptide-1  receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.TERN-701, an oral, allosteric BCR-ABL inhibitor is being evaluated for the treatment of chronic myeloid leukemia . TERN-701 has demonstrated superior efficacy and safety compared to traditional active-site tyrosine kinase inhibitors .Terns’ other pipeline candidates appear promising as well. The company is evaluating TERN-601, an oral, small-m","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc.","BK4588":"碎股","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4578":"CAR-T","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PK":"Park Hotels & Resorts Inc.","BK4218":"酒店及度假村房地产信托","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4181":"酒店及度假村房地产投资信托","BK4532":"文艺复兴科技持仓","TERN":"Terns Pharmaceuticals, Inc.","NVS":"诺华","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","ALXO":"ALX Oncology Holdings","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4007":"制药"},"translate_title":"Terns(TERN)年初至今上涨13.6%：这种势头会持续吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":1,"PK":1,"NVS":1,"ALXO":1,"LGND":0.9},"content_text":"Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, is having a good run year to date (YTD).\nShares of the company have risen 13.6% YTD against the industry’s decline of 7%.\nImage Source: Zacks Investment Research\nThe outperformance can be attributed to encouraging pipeline progress.\nTerns is developing a portfolio of small molecule product candidates in the oncology and obesity space. The pipeline contains three clinical-stage development programs, including an allosteric BCR-ABL inhibitor, a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.\nTERN-701, an oral, allosteric BCR-ABL inhibitor is being evaluated for the treatment of chronic myeloid leukemia (CML). TERN-701 has demonstrated superior efficacy and safety compared to traditional active-site tyrosine kinase inhibitors (TKIs).\nA phase I study, CARDINAL, in CML is ongoing and interim data from the initial CARDINAL dose escalation cohorts are expected in the second half of 2024.\nIn April, Terns announced upbeat data from a phase I study of TERN-701 in Western healthy volunteers. The study is an ongoing phase I open-label, single ascending dose trial to evaluate the pharmacokinetics (PK), food effect, safety and tolerability of TERN-701 in healthy adults. Data indicated that TERN-701 can be administered once daily with or without food at doses that achieve clinically efficacious exposures.\nAccording to the company, TERN-701 has the potential to be a differentiated BCR-ABL inhibitor with advantages over Novartis’ NVS Scemblix (asciminib), including more convenient dosing to improve treatment options and quality of life for people living with CML.\nIn March 2024, the FDA granted orphan drug designation to TERN-701 for the treatment of CML.\nThe successful development of TERN-701 should be a significant boost for the company, given the market potential.\nThe cash position, which also looks good, should enable TERN to fund its development programs. As of Mar 31, 2024, cash, cash equivalents and marketable securities were $240.7 million. Based on its current operating plan, Terns expects these funds to be sufficient to support its planned operating expenses into 2026.\nNVS’ Scemblix is approved in several countries, including the United States and the EU, to treat adults with Ph+ CML-CP who have previously been treated with two or more TKIs.\nTerns’ other pipeline candidates appear promising as well. The company is evaluating TERN-601, an oral, small-molecule GLP-1 receptor agonist for obesity.\nA phase I first-in-human clinical trial in obese and overweight participants is progressing. The multiple ascending dose portion of the study is underway, evaluating once-daily administration of TERN-601.\nTerns is on track to report top-line 28-day weight loss data in the second half of 2024.  Obesity is a lucrative market that is in the spotlight following the stupendous success of Novo Nordisk’s Wegovy, among others.\nPositive data readouts from the ongoing studies should keep investors’ interest afloat and maintain momentum for Terns.\nMeanwhile, TERN ccontinues to evaluate opportunities for TERN-501, an oral, thyroid hormone receptor-beta (THR-β) agonist, in metabolic diseases.\nAs reported by Terns, THR-β is an orthogonal mechanism to GLP-1, potentially providing broader metabolic and liver benefits in addition to increased weight loss based on non-clinical studies.\nTerns is also prioritizing its discovery efforts on nominating a GIPR antagonist development candidate based on in-house discoveries and growing scientific rationale supporting the potential of GLP-1 agonist/GIPR antagonist combinations for obesity.\nZacks Rank & Other Stocks to Consider\nTerns carries a Zacks Rank #2 (Buy) at present.\nA couple of other top-ranked stocks in the biotech sector are Ligand Pharmaceuticals LGND and ALX Oncology Holdings ALXO, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share (EPS) has increased 16 cents to $4.71. During the same time frame, the consensus estimate for 2025 EPS has increased 70 cents to $5.90. Year to date, shares of LGND have risen 12.7%.\nLigand beat on earnings in each of the trailing four quarters, delivering an average surprise of 56.02%.\nIn the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.\nALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovartis AG (NVS) : Free Stock Analysis Report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nALX Oncology Holdings Inc. (ALXO) : Free Stock Analysis Report\nTerns Pharmaceuticals, Inc. (TERN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444402996"}